Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | KIF20A | O95235 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395847 | 0.89 | KDM4E (0.62) | KDM4EALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL11545107 | 0.87 | MTNR1A (0.56) | KDM4EALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL5329797 | 0.86 | NR4A2 (0.68) | MTNR1AMTNR1BHTR2ANR4A2KIF20A | |
| SCHEMBL5102654 | 0.86 | HTR2A (0.52) | KDM4EALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL11791315 | 0.86 | NR4A2 (0.52) | KDM4EALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL24995079 | 0.83 | HTR2A (0.51) | KDM4EALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL19997209 | 0.83 | CTNNB1 (0.52) | KDM4EALDH1A1MTNR1AMTNR1BHTR2A | |
| SCHEMBL17321397 | 0.83 | MTNR1A (0.52) | KDM4EALDH1A1HPGDMTNR1AMTNR1B | |
| SCHEMBL6031099 | 0.83 | MTNR1A (0.52) | KDM4EALDH1A1MTNR1AMTNR1BHTR2A | |
| SCHEMBL7386422 | 0.82 | NR4A2 (0.49) | KDM4EALDH1A1HPGDMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230234984-A1 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | ANIXA BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2018009539-A1 | INHIBITORS OF HEXOKINASE AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2018-01-11 | — | — | WO | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3166940-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | Alpharmagen, LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-5723462-A | SLEEP AND SEIZURE DISORDERS; COGNITION ACTIVATORS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0825193-A1 | Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0821685-A1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1998002420-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5608079-A | MEMORY ENHANCEMENT IN BRAINS | NEUROGEN CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996033196-A1 | INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5567711-A | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0725775-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1996-08-14 | — | — | EP | disclosed |
| US-5484944-A | ANXIETY, SLEEP, MEMORY | NEUROGEN CORPORATION (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995011885-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234984-A1 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | SERPINB1, PREP, HPN | KDM4E 4586/4885ALDH1A1 2984/4885HPGD 681/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | KDM4E 3528/4885ALDH1A1 1497/4885HPGD 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.